Starting later this year, Ouro intends to start a phase 1 clinical trial of its own, eyeing the development of the drug for ...

We are delighted to welcome Kristen and Nancy to our Board of Directors,” said Tom King, Executive Chairman of Achieve’s Board of Directors. “Their wealth of knowledge and experience in strategic ...

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from ...

Kotak Strategic Situations India Fund Il, managed by Kotak Alternate Asset Managers Ltd, has made an investment  Rs 940 crore ...

Previously at MeiraGTx, GSK and Novartis, Dr. Leighton will help Chemify scale the company’s operational capacity to meet ...

Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference at 6:45 p.m. ET / 3:45 p.m. PT on January 14, 2025. The webcast will be accessible from Royalty Pharma's "Events” page ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Neuberg Diagnostics, a diagnostics chain headquartered in India, raised Rs 940 crore from Kotak Alternate Asset Managers Ltd.

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...